Search Results

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization

December 2021 Crinetics Pharmaceuticals announced the formation of an independently operated new company and Crinetics to Collaborate on Multiple Additional targets SAN DIEGO, October 18, 2021 — Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization

March 2022 Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief Commercial Officer "SAN DIEGO – March 1, 2022 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization --Design Pharmaceuticals, a company redesigning small molecule drug discovery, today announced the closing Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like

November 2021 Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc Switzerland, November 15, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical pioneering allosteric modulation-based drug discovery and development, today announced that Janssen Pharmaceuticals , Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has successfully completed

July 2022 "Not even a PIPE financing could save X4 Pharmaceuticals from enacting layoffs and trimming

June 2022 "CRN04894 Selected for Oral Presentation SAN DIEGO, June 8, 2022 — Crinetics Pharmaceuticals

with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery "Apr.19.2022 Ono Pharmaceutical

Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical The NDA was submitted by Trevena’s partner, Jiangsu Nhwa Pharmaceutical, and follows completion by Nhwa

Exploring Intracellular Targets: Bridging the Gap Between In Vitro and In Vivo GPCR Research - August 7th, 2025. Welcome back GPCR fans, The pace of GPCR innovation is accelerating at a rate that can be difficult to keep up with. For drug discovery teams and scientists, staying ahead requires more than just reading papers—it demands access to the right frameworks and expert insights that separate the noise from the signal. That’s exactly what Terry’s Corner delivers every week: practical tools from Dr. Terry Kenakin to elevate your science and sharpen your decisions. Breakthroughs this week: Glucagon-like Peptide-1 Receptor (GLP-1R) Signaling; Proximity-Dependent Proteomics; Multicolored sequential resonance energy transfer. 🔍 This Week in Premium: Sneak Peek Don't miss the key insights and opportunities that are shaping the future of GPCR research and drug discovery right now. This week's Premium content offers a curated look at what's moving the industry and scientific community forward. Industry insights:  Crinetics' Palsonify gains momentum in acromegaly, a key indicator for pipeline expansion; Septerna's chart signals upward expansion; and a look at how chronic diseases are driving growth in the global GPCR targeting market. Upcoming events:  Get details on the "neuroGPCR" symposium focusing on receptor signaling and a platform for unlocking "undruggable" targets with AI-powered hit discovery. Career opportunities:  New openings for a postdoctoral research position in GPCR biochemistry and biophysics and a research associate/scientist in in vitro pharmacology. Must-read publications:  A deep dive into proximity-dependent proteomics of adenylyl cyclase isoforms, a case for functionally Gs protein-selective GPCRs, and new methods for detecting simultaneous ligand binding. Terry's Corner : Unlock the Power of Intracellular GPCR Drugs For years, GPCR drug discovery has focused on targets at the cell surface. But what if the most significant opportunities lie just inside the cell membrane? This week Dr. Terry Kenakin delivers a game-changing framework for teams grappling with the gap between in vitro potency and in vivo performance. His latest lecture is a guide to understanding why intracellular drug access changes everything—from target residence time and rebinding kinetics to the discovery of previously untargetable sites. Solve the in vitro/in vivo disconnect:  Understand why traditional potency measurements often fail to predict clinical success and learn how intracellular kinetics can provide the missing link. Gain a competitive edge:  Learn to leverage restricted diffusion and rebinding to create drugs with longer therapeutic coverage, even with shorter systemic exposure. Avoid missed opportunities:  Discover how to identify and target cryptic intracellular allosteric sites, opening up new avenues for "failed" or under-studied GPCRs. To stay in the know on upcoming courses and AMA session, get the complementary Kenakin Brief , the weekly newsletter delivered directly to your inbox. Sharpen your discovery decisions ➤ Dr. GPCR Podcast : The Future of GPCR Drug Discovery with Molecular Modeling The field of GPCR research is being transformed by the accessibility of computational tools. In this week's Dr. GPCR Podcast, we sit down with Alessandro Nicoli, from the Technical University of Munich, to discuss his work on olfactory receptors. He shares his journey into computational chemistry and offers a compelling look at how tools like AlphaFold are providing new starting points for drug discovery. Learn how his research aims to develop models that can distinguish between active and inactive ligands, paving the way for computational ligand discovery even where experimental data is scarce. Harness the power of AI:  Discover how breakthroughs like AlphaFold are making previously "undruggable" targets, like olfactory receptors, accessible for computational analysis. Bridge the gap between disciplines:  Get practical advice from a computational expert on how wet-lab scientists can integrate computational tools like Python and Talktorials into their work. Learn from a pioneer:  Hear how mentorship and team science are fueling innovation in the field and providing a path for the next generation of GPCR scientists. Expand your computational toolkit ➤ Call for Papers: GPCRs: Signal Transduction, Volume II Building on the success of its first volume, the research topic "GPCRs: Signal Transduction: Volume II" is now open for submissions. This is a critical opportunity for the scientific community to come together and share new findings on how GPCRs regulate bodily functions, health, and disease. This research topic is designed to stimulate discussion and fuel the scientific direction of future GPCR research within the field of Cellular Biochemistry. Amplify your research:  Contribute to a high-impact collection of work that will shape the future of GPCR signaling studies. Connect with experts:  Join a community of like-minded field-experts dedicated to improving our collective understanding of GPCRs in human health. Stay ahead of the curve:  Showcase your latest findings on the essential role GPCRs play in disease and their function as important drug targets. Discover the research topic ➤ Why Dr. GPCR Premium Membership Gives You an Edge Staying at the forefront of GPCR science is not just a goal—it’s a necessity. The right information at the right time can mean the difference between a breakthrough and a dead end. Dr. GPCR Premium Membership delivers curated, noise-free intelligence every week: deep-dive expert lectures, classified industry news, priority event alerts, job opportunities, and insider commentary—designed to help you move faster, smarter, and with greater confidence. This isn’t just a newsletter; it's a strategic tool for your career and your science. “The best pharmacology teacher (Dr. Kenakin) teaming up with the best GPCR community platform to help train and inspire the next generation of scientists. Also super-valuable for those of us learning how to teach pharmacology” — Dr. GPCR Course Attendee FAQ: What You Get with Dr. GPCR Premium What’s included?  The complete Weekly News digest, curated jobs, upcoming events, classified GPCR publications, exclusive on-demand expert-led courses, and member-only discounts. Who is it for?  GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who need fast, curated, career-relevant intelligence to stay ahead. Why now?  The pace of GPCR innovation is accelerating. Those acting on the right signals today will shape tomorrow’s breakthroughs—and avoid delays others won’t see coming. Don’t Fall Behind—Access the Edge You Need 👉 Access all the news and upcoming events ➤ 👉 Already a Premium Member?  Read the Full Edition here ➤ The field of GPCRs is dynamic and competitive. To succeed, you need to move beyond standard approaches and adopt the frameworks that are driving real innovation. Dr. GPCR Premium Membership gives you direct access to the experts and insights that can redefine your work. Don’t wait for others to lead—become a Premium Member today and access the intelligence that will power your next breakthrough.

monoclonalantibodies #drugdiscovery #biotechnology #research #ionchannels #biologics #biotech #pharma #pharmaindustry #pharmaceuticals

Born near Venice and trained as a pharmaceutical chemist, Alessandro never imagined himself working at The Early Days: Molecules and Mentors Alessandro began his academic life studying pharmaceutical chemistry

She studied pharmacy with a specialization in pharmaceutical chemistry, a degree that allowed her to

Therapeutics To Release Half-Year 2023 Financial Results And Host Conference Call On August 10, 2023 X4 Pharmaceuticals adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results And Provides Corporate Update X4 Pharmaceuticals Announces

- 4, 2024 | Chemotactic Cytokines GPCR Jobs NEW Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals NEW Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

Jobs NEW Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

Apprentice Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical

recently had the pleasure of speaking with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals

research in biomedical sciences with the mechanistic understanding of one of the biggest classes of pharmaceutical

GPCR Jobs Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

elusive GPCR targets, financial results from Neurocrine Biosciences, and a deep dive into Crinetics Pharmaceuticals Yamina's Corner, biotech, systems thinking, signal transduction, operational excellence, drug development, pharmaceutical

"Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical

Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical

Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 Crinetics Pharmaceuticals Cushing’s Syndrome (ADCS) Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals

Geneva, Switzerland, April 6, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical

Tagging GPCRs expressed in cellular compartments such as the nucleus or endosomes presents several pharmaceutical Overall, the pharmaceutical challenges associated with tagging GPCRs expressed in cellular compartments Pharmaceuticals (Basel, Switzerland), 14(5), 439. https://doi.org/10.3390/ph14050439 Chen, K.

expansion as the leading GPCR immuno-oncology company Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer Rhythm Pharmaceuticals and LG Chem Life Sciences

Multi-Product Pipeline Toward Clinical Studies Confo Therapeutics Appoints Dieter Weinand, Former CEO Of Bayer Pharmaceuticals Wainwright 25th Annual Global Investment Conference X4 Pharmaceuticals to Participate in the Morgan Stanley

"Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical